Randomized Trials: Shorter Duration of Dual Antiplatelet Therapy May be an Option for Patients Undergoing Percutaneous Coronary Intervention

Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial – JAMA (free for a limited period)

Related Study: Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Dual Antiplatelet Therapy: Is It Time to Cut the Cord With Aspirin? (free for a limited period)

Audio Summary: Reducing the Intensity of Antithrombotic Therapy Following Coronary Stent Procedures (free)

Commentaries: Shorter Dual Antiplatelet Therapy May Be an Option for Patients Undergoing PCI – NEJM Journal Watch (free) AND Short and Optimal Duration of Dual Antiplatelet Therapy After Everolimus-Eluting Cobalt-Chromium Stent-2 – STOPDAPT-2 – American College of Cardiology (free)

Related Commentary on Twitter

Among patients undergoing PCI, aspirin and clopidogrel therapy (DAPT) for 1 vs 12 months resulted in a lower rate of CV and bleeding events, meeting criteria for both noninferiority and superiority https://t.co/OJ76qrEGiq

— JAMA (@JAMA_current) June 25, 2019